Thursday, August 22, 2019

Merck Wins Additional HHS Funding For Ebola Vaccine In DRC; And A Potential For A Cure Emerges...


I am very tardy with these twin bits of news, but HHS/BARDA has now granted Merck a total of over $176 million -- as the company develops and manufactures the Ebola vaccine -- widely deployed in the DRC, this go 'round.

And an expensive, but highly effective treatment has emerged in other research -- too early to call it a cure, to be sure -- but very promising. Now the trick will be convincing the good people on the ground that they ought to be treated. Here's a bit of that from last week [H/T, to the erstwhile Anon. -- via STAT -- under the expert eye of Helen Branswell, here]:

. . . .[T]o declare victory against the virus would be to overlook fundamental truths about outbreaks. In some circumstances at least — and the current long-running outbreak is one — Ebola will not be vanquished by vaccines and drugs alone.

“I think the news today is fantastic. It gives us a tool in our toolbox against Ebola. But it doesn’t in itself stop Ebola,” Dr. Mike Ryan, who runs the World Health Organization’s health emergencies program, told reporters earlier this week, sounding somewhat subdued, as health officials announced that for the first time a clinical trial had shown an Ebola treatment was helping people survive the virus. . . .

“What will stop Ebola is. . . good surveillance, good infection prevention and control, good community engagement, excellent vaccination and the use of these therapeutics in the most effective way possible, in safe and humane Ebola treatment units. It’s not one answer. It’s many things. . . .”


Indeed. Onward, with renewed hope. . . .

नमस्ते

No comments: